Cart
sales@molnova.com
329-Dibenzoyl Rarounitriol
CAS No. 873001-54-8
329-Dibenzoyl Rarounitriol( —— )
Catalog No. M20298 CAS No. 873001-54-8
329-Dibenzoyl karounitriol is a natural product from Trichosanthes kirilowii Maxim.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 90 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name329-Dibenzoyl Rarounitriol
-
NoteResearch use only, not for human use.
-
Brief Description329-Dibenzoyl karounitriol is a natural product from Trichosanthes kirilowii Maxim.
-
Description329-Dibenzoyl karounitriol is a natural product from Trichosanthes kirilowii Maxim.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number873001-54-8
-
Formula Weight666.94
-
Molecular FormulaC44H58O5?
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (37.49 mM)
-
SMILES[H][C@@]12C[C@H](O)C3=C(CC[C@@]4(C)[C@]5([H])C[C@](C)(COC(=O)c6ccccc6)CC[C@]5(C)CC[C@]34C)[C@@]1(C)CC[C@@H](OC(=O)c1ccccc1)C2(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yan Z Hai-Yan Y Yu-Ting S et al. Quality control of GualouXiebai drop pills[J]. Chinese Journal of Hospital Pharmacy 2014.
molnova catalog
related products
-
DO-264
DO-264 is an inhibitor of autohydrolase structural domain 12 (ABHD12) (IC50: 11 nM) and an inhibitor of cellular LysoPS degradation that enhances LPS-induced phagocytosis.
-
Growth Hormone Relea...
Growth Hormone Releasing Factor, GRF (1 - 40), amide, human
-
116-9e
116-9e (MAL2-11B) is a potent Hsp70 co-chaperone DNAJA1 inhibitor with antiviral properties, inhibiting simian virus 40 (SV40) replication, tumour antigen (TAg) endogenous ATPase activity, and TAg-mediated activation of Hsp70. 116-9e can be used to study cancer drug resistance.
